Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jun 17;1(5):516–534. doi: 10.1016/j.jcmgh.2015.06.009

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Exome sequencing of primary tumor and cell-free DNA. (A) The clinical course of case C1. Case C1 had one combined hepatocellular and cholangiocarcinoma (cHCC/CC) lesion in the right lobe that was removed by curative resection. Transcatheter arterial chemoembolization (TACE) was performed for intrahepatic recurrent lesions 2 years after the first surgery. We performed exome sequencing of cell-free DNA after the TACE and the primary tumor (red star). (B) The amount of total cell-free DNA extracted from the plasma samples serially obtained after TACE. Cell-free DNA was most abundant in plasma 2 days after TACE, and was therefore used for exome sequencing analysis. (C) Common mutations in cell-free DNA and primary tumor. Somatic mutations detected by probabilistic variant detection and low frequency variant detection are indicated by the red and pink boxes, respectively.

Exome sequencing of primary tumor and cell-free DNA. (A) The clinical course of case C1. Case C1 had one combined hepatocellular and cholangiocarcinoma (cHCC/CC) lesion in the right lobe that was removed by curative resection. Transcatheter arterial chemoembolization (TACE) was performed for intrahepatic recurrent lesions 2 years after the first surgery. We performed exome sequencing of cell-free DNA after the TACE and the primary tumor (red star). (B) The amount of total cell-free DNA extracted from the plasma samples serially obtained after TACE. Cell-free DNA was most abundant in plasma 2 days after TACE, and was therefore used for exome sequencing analysis. (C) Common mutations in cell-free DNA and primary tumor. Somatic mutations detected by probabilistic variant detection and low frequency variant detection are indicated by the red and pink boxes, respectively.